drugset / Trial / NCT02386826
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
Timeline
- Start
- 2015-09-22
- Primary completion
- 2021-07-31
- Completion
- 2023-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Capmatinib | Small molecule | 100 mg | Oral |
| Subject | Capmatinib | Small molecule | 200 mg | Oral |
| Subject | Capmatinib | Small molecule | 400 mg | Oral |